ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,870Medicare Part D Prescriptions Filled, Including Refills

Rank: 9 out of 143

$666K Total Retail Price of All Prescriptions

Rank: 15 out of 143

487 Patients Receiving at Least One Drug in Part D
72%Patients 65 Years and Older
55% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Delaware
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 487 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

5% of this provider’s 487 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

2% of this provider’s 6,661 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$75 was the average price of a prescription from this provider, compared to $79 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Delaware
LISINOPRIL 372 301 1 1
METFORMIN HCL 288 210 2 8
AMLODIPINE BESYLATE 281 234 3 4
HYDROCHLOROTHIAZIDE 266 187 4 10
PRAVASTATIN SODIUM 233 195 5 9
OMEPRAZOLE 230 164 6 5
LEVOTHYROXINE SODIUM 198 174 7 3
FUROSEMIDE 196 160 8 6
METOPROLOL SUCCINATE 192 132 9 14
SIMVASTATIN 174 156 10 2
ATORVASTATIN CALCIUM 155 123 11 7
GLIPIZIDE 126 76 12 55
METOPROLOL TARTRATE 123 109 13 12
LISINOPRIL-HYDROCHLOROTHIAZIDE 117 106 14 21
TRAMADOL HCL 110 74 15 16
BISOPROLOL FUMARATE 100 67 16 67
ISOSORBIDE MONONITRATE ER 98 88 17 44
ZOLPIDEM TARTRATE 86 62 18 13
ATENOLOL 86 82 18 11
DONEPEZIL HCL 84 78 20 36
PROAIR HFA 80 56 21 48
LANTUS SOLOSTAR 78 56 22 66
HYDROCODONE-ACETAMINOPHEN 78 65 S3 22 20
OXYCODONE HCL 77 57 S2 24 29
RANITIDINE HCL 74 49 25 41
SPIRIVA 73 58 26 38
CLOPIDOGREL 73 55 26 33
WARFARIN SODIUM 69 31 28 15
SERTRALINE HCL 68 39 29 23
CIPROFLOXACIN HCL 68 55 29 58
PREDNISONE 67 41 31 35
TRILIPIX 66 58 32 197
GABAPENTIN 65 41 33 18
AZITHROMYCIN 63 46 34 31
NAMENDA 62 57 35 49
POLYETHYLENE GLYCOL 3350 62 51 35 45
CRESTOR 61 44 37 17
ADVAIR DISKUS 59 44 38 42
PLAVIX 58 46 39 51
LEVOFLOXACIN 58 42 39 68
ALENDRONATE SODIUM 56 51 41 40
CITALOPRAM HBR 55 54 42 25
PANTOPRAZOLE SODIUM 55 35 42 43
ALLOPURINOL 54 41 44 39
CARVEDILOL 53 44 45 22
NIASPAN 52 24 46 105
FLUTICASONE PROPIONATE 51 24 47 37
HYDRALAZINE HCL 50 42 48 64
LOSARTAN POTASSIUM 50 14 48 19
GLIPIZIDE ER 50 35 48 75
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 4, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.